Salt sensitivity and timed drug therapy in arterial hypertension. Enhancing antihypertensive drug efficacy: a controlled randomised trial

Background. An elevated or inadequate sensitivity to salt intake is an important mechanism for maintaining high blood pressure in patients with arterial hypertension. Chronopharmacotherapy comprises an important approach to control arterial hypertension through personalised correction of blood pressure but requires a further proof of efficacy in salt-sensitive hypertensive patients.

Objectives. An assessment of six-month dynamics of diurnal and nocturnal peripheral and central blood pressure in salt-sensitive patients with arterial hypertension under chronopharmacothe­rapy.

Methods. A controlled randomised trial included 86 salt-sensitive patients with arterial hypertension. Salt sensitivity was estimated with a Kharchenko’s test. All patients had circadian monitoring of the peripheral and central blood pressure and glomerular filtration rate at baseline and in a six-month follow-up. The patients were randomised into 3 cohorts. Cohort A united patients received perindopril and amlodipine in morning, cohort B — perindopril in morning, amlodipine in evening, cohort C — perindopril in evening, amlodipine in morning. Statistica 12 (StatSoftInc, USA) was used for nonparametric statistical analyses.

Results. In six months of chronopharmacotherapy a target arterial pressure was registered in 87.5% patients in cohort A, 96.4 and 96.2% patients in cohorts B and C, respectively. All cohorts exhibited a declining peripheral and central blood pressure over therapy. Cohort A had a greater decline in daytime, and cohorts B and C — both diurnally and nocturnally. Cohorts B and C had more patients with an adequate nocturnal blood pressure decline. Glomerular filtration rate also elevated with perindopril or amlodipine intake before bedtime.

Conclusion. The perindopril or amlodipine intake before bedtime in a combined therapy for arterial hypertension provided for a target blood pressure in the overall majority of patients, effectively reduced peripheral and central blood pressure at all time intervals, contributed to optimising the circadian blood pressure profile and increased the glomerular filtration rate.

1. Rahimi K., Emdin C.A., MacMahon S. The epidemiology of blood pressure and its worldwide management. Circ. Res. 2015; 116(6): 925–936. DOI: 10.1161/CIRCRESAHA.116.304723

2. Konradi A.O., Nedogoda S.V., Nedoshivin A.O., Ratova L.G., Libis R.A., Arutyunov G.P., Borovkova N. Yu., Galyavich A.S., Grinshtein Yu. I., Duplyakov D.V., Kashtalap V.V., Lopatin Yu. M., Lyamina N.P., Malchikova S.V., Mikhin V.P., Nechaeva G.I., Ostroumova O.D., Ripp T.M., Chumakova G.A., Shaposhnik I.I., Yakusevich V.V. Modern antihypertensive therapy: the effectiveness of a unique russian fixed–dose combination of ramipril and indapamide. Russian Journal of Cardiology. 2020; 25(3): 89–97 (In Russ., English abstract). DOI: 10.15829/1560-4071-2020-3-3782

3. Elijovich F., Weinberger M.H., Anderson C.A., Appel L.J., Bursztyn M., Cook N.R., Dart R.A., Newton-Cheh C.H., Sacks F.M., Laffer C.L.; American Heart Association Professional and Public Education Committee of the Council on Hypertension; Council on Functional Genomics and Translational Biology; and Stroke Council. Salt sensitivity of blood pressure: a scientific statement from the American Heart Association. Hypertension. 2016; 68(3): e7–e46. DOI: 10.1161/HYP.0000000000000047. Erratum in: Hypertension. 2016; 68(4): e62.

4. Morris R.C. Jr, Schmidlin O., Sebastian A., Tanaka M., Kurtz T.W. Vasodysfunction That Involves Renal Vasodysfunction, Not Abnormally Increased Renal Retention of Sodium, Accounts for the Initiation of Salt–Induced Hypertension. Circulation. 2016; 133(9): 881–893. DOI: 10.1161/CIRCULATIONAHA.115.017923

5. Cheng H.M., Chuang S.Y., Wang T.D., Kario K., Buranakitjaroen P., Chia Y.C., Divinagracia R., Hoshide S., Minh H.V., Nailes J., Park S., Shin J., Siddique S., Sison J., Soenarta A.A., Sogunuru G.P., Sukonthasarn A., Tay J.C., Teo B.W., Turana Y., Verma N., Zhang Y., Wang J.G., Chen C.H. Central blood pressure for the management of hypertension: Is it a practical clinical tool in current practice? J. Clin. Hypertens. (Greenwich). 2020; 22(3): 391–406. DOI: 10.1111/jch.13758

6. Hermida R.C., Mojón A., Fernández J.R. Bedtime hypertension chronotherapy best reduces cardiovascular disease risk as documented by MAPEC and Hygia Chronotherapy outcomes trials. Chronobiol. Int. 2020; 37(5): 731–738. DOI: 10.1080/07420528.2020.1771354

7. Hermida R.C., Crespo J.J., Domínguez-Sardiña M., Otero A., Moyá A., Ríos M.T., Sineiro E., Castiñeira M.C., Callejas P.A., Pousa L., Salgado J.L., Durán C., Sánchez J.J., Fernández J.R., Mojón A., Ayala D.E.; Hygia Project Investigators. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur. Heart. J. 2020; 41(48): 4565–4576. DOI: 10.1093/eurheartj/ehz754

8. Skibitskiy V.V., Kiselev A.A., Fendrikova A.V. Effectiveness of chrono–pharmacotherapy depending on the salt sensitivity of patients with arterial hypertension and diabetes mellitus type 2. Rational Pharmacotherapy in Cardiology. 2018; 14(6): 846–851 (In Russ., English abstract). DOI: 10.20996/1819-6446-2018-14-6-846-851

9. Kobalava Z.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I., Barbarash O.L., Boitsov S.A., Vavilova T.V., Villevalde S.V., Galyavich A.S., Glezer M.G., Grineva E.N., Grinstein Yu.I., Drapkina O.M., Zhernakova Yu.V., Zvartau N.E., Kislyak O.A., Koziolova N.A., Kosmacheva E.D., Kotovskaya Yu.V., Libis R.A., Lopatin Yu.M., Nebiridze D.V., Nedoshivin A.O., Ostroumova O.D., Oschepkova E.V., Ratova L.G., Skibitsky V.V., Tkacheva O.N., Chazova I.E., Chesnikova A.I., Chumakova G.A., Shalnova S.A., Shestakova M.V., Yakushin S.S., Yanishevsky S.N. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020; 25(3): 3786 (In Russ.). DOI: 10.15829/1560-4071-2020-3-3786

10. Glezer M.G. The use of fixed perindopril a/amlodipine combination provides high compliance to therapy, effective and safe arterial pressure lowering in patients with previous inefferctive therapy. The POTENTIAL program. Kardiologiia. 2015; 55(12); 17–24 (In Russ., English abstract). DOI: 10.18565/cardio.2015.12.17-24

11. Dobryninа N.V., Yakushin S.S. Effective blood pressure reduction: results of the regional program “DOVERIE”. Russian Journal of Cardiology. 2018; (12): 57–63 (In Russ., English abstract). DOI: 10.15829/1560-4071-2018-12-57-63

12. Degli Esposti L., Perrone V., Veronesi C., Gambera M., Nati G., Perone F., Tagliabue P.F., Buda S., Borghi C. Modifications in drug adherence after switch to fixed–dose combination of perindopril/amlodipine in clinical practice. Results of a large-scale Italian experience. The amlodipine-perindopril in real settings (AMPERES) study. Curr. Med. Res. Opin. 2018; 34(9): 1571–1577. DOI: 10.1080/03007995.2018.1433648

13. Glezer M.G. Antihypertensive Effect of Switching to a Fixed Perindopril/Amlodipine Combination in Patients Ineffectively Treated by Free Sartan-Containing Combinations. Results of the AVANGARD Study. Kardiologiia. 2019;59(10):31–38 (In Russ., English abstract). DOI: 10.18087/cardio.2019.10.n731

14. Astashkin E.I., Glezer M.G. Mechanisms of combined action of ace inhibitors and calcium antagonists in arterial hypertension. Cardiovascular Therapy and Prevention. 2013; 12(3): 72–77 (In Russ., English abstract). DOI: 10.15829/1728-8800-2013-3-72-77

15. Hermida R.C., Hermida-Ayala R.G., Smolensky M.H., Mojón A., Fernández J.R. Ingestion-time — relative to circadian rhythms — differences in the pharmacokinetics and pharmacodynamics of hypertension medications. Expert. Opin. Drug. Metab. Toxicol. 2020; 16(12): 1159–1173. DOI: 10.1080/17425255.2020.1825681

16. Khodadoustan S., Nasri Ashrafi I., Vanaja Satheesh K., Kumar C., Hs S., S. C. Evaluation of the effect of time dependent dosing on pharmacokinetic and pharmacodynamics of amlodipine in normotensive and hypertensive human subjects. Clin. Exp. Hypertens. 2017; 39(6): 520–526. DOI: 10.1080/10641963.2017.1281947